**Title:** A METHOD AND AN APPARATUS FOR DETERMINING HAEMODYNAMIC STATUS

**Abstract:** A device and a method thereof for determining a haemodynamic state of an individual from a magnitude of a perfusion signal or a signal which is a measure of a volume of blood in the thoracic cavity of the individual, wherein the control device is configured to receive a first signal and a heart rate signal, divide the first signal into frames, wherein a frame length is determined from an oscillation period of the heart rate signal, and determine a magnitude of the first signal from at least two frames, so as to obtain a more reliable magnitude of the first signal.

---

**Fig. 3**
don National Heart and Lung Institute, Hammersmith Hospital Campus, B Block, 2nd Floor, NHLI Cardiovascular Science, Du Cane Road, London W12 ONN (GB).

(74) Agent: ARENDNS, William Gerrit; Marks & Clerk LLP, 90 Long Acre, London WC2E 9RA (GB).


Published: with international search report (Art. 21(3))
A method and an apparatus for determining haemodynamic status

FIELD OF THE INVENTION

The present invention relates generally to a device for determining a haemodynamic state of an individual from a magnitude of a perfusion signal, a control system comprising a device configured to output a signal to a device for haemodynamic intervention based on a haemodynamic state of an individual determined from a magnitude of a perfusion signal and methods thereof.

BACKGROUND OF THE INVENTION

Cardiac arrhythmia are a group of conditions known in the field of cardiology in which the heartbeat is irregular, too fast or too slow when compared to a normal heartbeat. Various different implantable or externally wearable devices can be used to treat more serious types of arrhythmia, which may cause the individual symptoms such as dizziness, passing out, heart failure or death. Ventricular tachycardia (VT) is a type of cardiac arrhythmia which originates from the ventricles (the main pumping chambers of the heart). In VT, the heartbeat is too fast, for example above 100 beats per minute, and this is one of the more serious types of arrhythmia. VT is often treated using an implantable cardioverter defibrillator (ICD) or externally wearable defibrillator, which delivers a therapy in a form of a rapid sequence of electrical impulses (overdrive pacing) or an electrical shock (defibrillation) to the heart, in an attempt to restore a normal rhythm in the heartbeat.

An ICD and other implantable or externally wearable devices that monitor and/or treat cardiac arrhythmia may use various physiological parameters for monitoring an individual's conditions and for managing or controlling therapies delivered to an individual. The most commonly used physiological parameter for determining the individual's cardiac condition are measurement of electrical signals originating from the ventricles in the heart (the main pumping chambers). In general, such cardiac electrical signals represent the heartbeat. Whilst cardiac electrical signals can be used as an indicator of the individual's condition, under some circumstances the information obtained from the cardiac electrical signal may not be sufficient to determine the
individual's condition and hence make a decision on whether a therapy should be
delivered by the implantable or externally wearable device or not.

For example, in some cases, the individual's condition may not even be reflected in the
cardiac electrical signal. An example of such case is illustrated in Figures 1A and 1B. The two figures illustrate example signals received from an individual who suffers from
VT. As mentioned above, VT is a type of tachycardia, which causes improper electrical
activity of the heart and hence abnormal heart rhythm, often causing a rapid heartbeat.
As noted above, the implantable device relevant to VT is an ICD, which delivers a
therapy in a form of a rapid sequence of electrical impulses or an electrical shock to the
heart, in an attempt to restore a normal rhythm. Externally wearable defibrillators may
also be used. In some cases, VT may be well tolerated so that it does not actually
require a therapy to be delivered. In the case of a well-tolerated VT, it is highly
preferable to delay or even omit the delivery of a therapy, as an unnecessary therapy
can be harmful and/or uncomfortable. For example, sometimes the rapid sequence of
electrical impulses (overdrive pacing) can cause VT to deteriorate into a worse form of
VT. As another example, electric shocks (defibrillation) are uncomfortable and may
even worsen the long-term function of the heart causing an increased probability of
death in the long term. However, it is difficult to distinguish such well tolerated VT from
an electrocardiogram (ECG) signal, which is a cardio electrical signal, alone. As yet
another example, an ICD lead which is configured to sense the electrical signal of the
heart may be damaged, for example due to fracture. This may cause noise to be
included in the sensed electrical signal, and such noise can be incorrectly interpreted
as an arrhythmia (VT or Ventricular Fibrillation (VF)).

In both Figures 1A and 1B, the data collected during sinus rhythm illustrate data
collected where the heart of the individual is working normally, and the data collected
during simulated VT illustrate data collected during VT. The horizontal axis represents
time. For Figure 1A, VT occurs around 00:22, and for Figure 1B, VT occurs around
00:27. Looking at the ECG signal, it is clear when VT occurs in both cases. The ECG
signals in Figures 1A and 1B are not significantly different and an ICD relying solely on
the ECG signal would determine that the individual requires a therapy to be delivered in
both cases of Figure 1A and Figure 1B, in view of the increased heart rate that falls
within a predetermined abnormal range. Studying the relevant blood pressure signal
(BP signal), which indicates the haemodynamic state of the individual; a different
conclusion regarding the delivery of a therapy can be reached. In the case of Figure 1A, it can be seen that the blood pressure does not fall significantly even after VT start at 00:20. This indicates a well-tolerated VT, which is defined as VT which is associated with preserved cardiac output. As can be seen by the drop in the blood pressure, cardiac output may decline compared to normal sinus rhythm but is sufficient to ensure that perfusion to the brain and other major organs is preserved. Individuals under well tolerated VT therefore do not feel dizzy or lose consciousness. In contrast, the BP signal in Figure 1B drops significantly when VT occurs, which indicates that this VT is not well tolerated and there is not enough cardiac output to ensure that perfusion to the essential major organs are being achieved. As such, a delivery of a therapy is necessary in the case illustrated in Figure 1B.

Unfortunately, BP signals are not readily available to implantable or externally wearable devices for constant monitoring. In the place of BP signals, it has been found that tissue perfusion signals can also indicate haemodynamic state of an individual, much like a BP signal. A tissue perfusion signal can be acquired by a number of different methods including laser Doppler, spectroscopy and ultrasound Doppler. As an example, tissue perfusion signals obtained using a laser Doppler method are illustrated in Figure 1A and Figure 1B. As can be seen in Figure 1A, the perfusion signal also maintains some perfusion level, even if lower than in a normal sinus rhythm, during a well-tolerated VT. As illustrated in Figure 1B, perfusion signal also decreases dramatically during VT which is not well tolerated. Therefore, perfusion signal can be used as a useful indicator to determine the individual's condition for use in deciding whether a therapy needs to be delivered or not.

An example of an ICD system including a tissue perfusion sensor module is disclosed in US 2013/0030307 A1. Here, both the ECG signal and the perfusion signal measurement are used to determine whether a therapy should be delivered or not. The problem with such a system is that signals derived from local perfusion data are labile in the presence of the individual's movement, position, placement of the sensor, orientation either within the body or, if externally positioned, the position of the sensor externally. In particular, if the individual collapses and then twitches (a common occurrence upon fainting) or is shaken by another person, then this motion can generate an artificial fluctuation in the tissue perfusion signal whose frequency may lie in the range of frequencies that might be expected from genuine beating of the heart.
and therefore may be difficult to distinguish from genuine beating of the heart. The possibility of this makes the tissue perfusion signal, on its own, an unreliable indicator of whether the patient is genuinely having perfusion of the organs. As such, regardless of the method used to obtain tissue perfusion signal, currently known methods of sensing and processing of the tissue perfusion signals are prone to being affected by relatively large artificial ("noise") components hence limiting the reliability and clinical utility of using haemodynamic status derived from the processed perfusion signal. This will be illustrated later with examples.

As such, the device according to the present invention processes the perfusion data to produce a signal which is not prone to being affected by high noise components of the signal and hence derives haemodynamic status of the individual in a reliable manner. Whilst an ICD device is mentioned as an example application of the present invention, it will be appreciated by the skilled reader that a reliable detection of a haemodynamic state would be useful for many other implantable or externally wearable devices such as pacemakers or nerve stimulators, and hence the present invention may be used in conjunction with various different implantable or externally wearable devices including an ICD device.

The present invention seeks to provide a method and an apparatus which is able to determine the individual's condition more reliably for monitoring the individual's condition and for guiding therapy delivery by an implantable or externally wearable device. The present invention further seeks to address, overcome or mitigate at least one or other disadvantages associated with the previously-known method and apparatus for determining the individual's condition to determine whether a therapy should be delivered by an implantable or externally wearable device or not.

SUMMARY OF THE INVENTION

According to an aspect of the present invention there is provided a device for determining a haemodynamic state of an individual from a magnitude of a first signal, wherein the first signal is a perfusion signal or a signal which is a measure of a volume of blood in the thoracic cavity of the individual, wherein the device is configured to: receive the first signal and a signal representative of the heart rate from the individual; divide the first signal into frames, wherein a frame length is determined from an
oscillation period of the heart rate signal; and determine a magnitude of the first signal from at least two frames.

A signal which is a measure of the volume of blood in the thoracic cavity may be a lead impedance signal for example.

Haemodynamic state describes whether the perfusion of a relevant body part (e.g. an organ) of an individual is adequate or not. It is a continuum with many possible levels between very good haemodynamic and very poor haemodynamic. In the present invention, the haemodynamic state is indicated as a value, wherein this value corresponds to a magnitude of a perfusion signal. This haemodynamic state, which is a variable value, may be compared against predetermined threshold values or other indicative marker values to determine whether the perfusion at the relevant body part is adequate or not. A series of haemodynamic state values may be determined continuously. This may also happen in real time as the perfusion signal is being acquired, or over a period of time for a perfusion signal which has already been acquired.

An indication of the haemodynamic state of the individual can also be indicated as a measure of the volume of blood in the thoracic cavity.

In an embodiment, the first signal is a perfusion signal. The heart rate signal may carry electrocardiogram data of the individual. The frame length may be determined solely in a time domain. The signal being processed solely in a time domain minimises the processing power requirement of the control device. The divided perfusion signal oscillates in synchrony with an oscillation of a heartbeat derivable from the heart rate signal. The segmented perfusion signal does not necessarily oscillate in the same phase, and may oscillate with a phase shift from the oscillation of the heartbeat. Each perfusion signal frame may oscillate in synchrony with an oscillation of a heart beat corresponding to the specific perfusion signal frame. The oscillation period may be intervals between successive cardiac cycles such as R wave-to-R wave intervals. R waves may be the easiest to detect. Any other fiducial marker may be used. The device may be further configured to perform a correction of any mismatch between the phase of the perfusion signal and the phase of the heart rate signal.
The device may be configured to combine at least two frames of the divided perfusion signal.

At least two segments of perfusions signals corresponding to perfusion signal of at least two frames may be combined according to the coherency of the frame. The multiple perfusion signal frames may be combined by being summated first. The multiple perfusion signal frames may be combined by being averaged. The multiple frames of perfusion signals may be combined by many different methods including the mean, median or Winsorized mean.

The device may find the magnitude of the perfusion signal as an amplitude of the combined perfusion signal. This may include the amplitude being an absolute value, a relative value, or a function thereof.

The amplitude of the summated signal may be found using various methods including the range of the data, standard deviation, or interquartile range.

Using the relationship between heart beat signal and the perfusion signal, general position of the relevant peak and trough can be predicted. By basing the frame length on an oscillation period of the heart rate signal, a single trough and a single peak corresponding to a single heartbeat are expected to be in a single frame. Such peak and trough caused by a heartbeat in each frame correspond in position on a time scale. Any noise in the signal or any peak or trough that are merely noise may be discounted as a result of the summation of the divided perfusion signal, as the peak and the trough that have been caused by the heart beat will correspond in time in every frame. The frames may be standardised. In other words, where the frame length vary due to any variation in heart rate, before summation the frames are adjusted such that the frame lengths are the same for all the frames.

The device may be configured to standardize the perfusion signal prior to combining at least two frames of the perfusion signal.

The perfusion signal frames may be standardized using one of many methods including subtraction of the mean, or performing a linear regression and subtracting the result of this.
The device may be configured to standardize the perfusion signal prior to combining at least two frames of the perfusion signal.

In the device, the frame length may be determined from an average oscillation period of the heart rate signal.

The heart rate signal acquired over a certain period of time may be used for calculating an average oscillation period. In other embodiments, the frame length may vary from segment to segment. In this case, the frame length may be determined from the corresponding specific R-R interval of an associated heart rate signal. The frames of the perfusion signal can then be modified so that they are all of the same length before summation. Frames of the perfusion signal which are determined to deviate substantially in length may not be included in the summation, for example, frames which deviate in length by more than 100 ms from a benchmark length may be excluded, or frames which deviate in length by more than 25% from a benchmark length may be excluded.

The device may be configured to output a confidence measure value which indicates the similarity of the divided perfusion signals in different frames that have been combined.

Such similarity among the segmented perfusion signals that have been summed may be found using correlation coefficient, standard deviation from the mean of the summated signal, or concordance of the sign of the signal after subtraction of the mean. Many other methods known to the skilled person may be used.

The device may be configured to receive a multiple number of perfusion signals and determine a magnitude of each perfusion signal from at least two frames of the same perfusion signal.

In some cases, perfusion signals from a number of sensors may be received by the device. The plurality of sensors may be placed in or on different parts of the patient and hence be configured to obtain perfusion signals from different parts of the patient. In other cases, the plurality of sensors may be closely located, for example in a single
device, but being pointing in different directions. A device having a plurality of sensors can be robust against any false or low quality perfusion signal that may be received. This is because there is lower chance of both sensors being faulty or collecting low quality, such that even if one of the sensors is not providing a high quality signal, the device can rely on the other sensor for high quality signal. The device may even compare the two signals to indicate whether one of the sensors seem to be faulty or should be re-positioned. In any case, where a plurality of perfusion signals are received from a plurality of sensors, the signal from each sensor is processed as described above. This is to say, each signal is divided into frames, wherein a frame length is determined from an oscillation period of the heart rate signal, and at least two frames of the same signal are combined to derive a magnitude of each signal, wherein the magnitude represents the local haemodynamic state of the individual at the location where the sensor is located. As such, a magnitude representing a local haemodynamic state of the individual can be obtained from each signal. Each of the magnitude may be considered separately to consider the local haemodynamic state of the individual, or the magnitudes obtained from signals obtained by different sensors may be combined to obtain an average haemodynamic state of the individual. The magnitudes from different signals may be combined using various different methods collating multiple values, such as averaging them, summing them up or taking the highest and the lowest values.

The sensor may be internal or external. The sensor may be a non-implantable haemodynamic sensor (for example on a watch) which senses the perfusion signal. The sensor may communicate remotely with the device. The sensor may be an externally wearable sensor.

The device itself may also be an externally wearable device, for example part of a watch. The device may comprise one or more sensors. The device may comprise a sensor to detect and generate a perfusion signal and/or a sensor to detect the heart rate from the individual. The device may comprise a non-implantable hemodynamic sensor.

The device may be configured to associate the perfusion signals with concurrently received heart rate signal.
The device may be configured to receive a plurality of heart rate signals from different sensors or leads, for example, atrial, left ventricular or electrodes implanted in the generator header. As mentioned above, damaged electrical sensors or ICD or external defibrillator leads can result in inappropriate shocks being delivered, due to the noise in the sensed signal being interpreted as VT or VF. In order to avoid this problem, the device may be configured to request for a different heart rate signal. In some embodiments, this is requested periodically to check if the electrical sensor or the ICD or external defibrillator lead are functioning correctly, or once the device determines that VF or VT is detected. For example, there may be present at least two of a left ventricular lead, a right ventricular lead, a left atrial lead and a right atrial lead. For example, where the device initially uses the heart rate signal from the left ventricular lead and determines that VF or VT is detected, it may request for heart rate signal from one of the atrial leads for use when dividing up the perfusion signal (i.e. to determine the frame length). If, based on the heart rate signal from the atrial lead, it is determined that the individual is in a normal rhythm, then the device determines that the ventricular lead is malfunctioning.

In other words, the device may be configured to determine the frame length for the perfusion signal based on different heart rate signals and compare the result to determine whether any of the sensors or leads obtaining the heart rate signal are faulty. The device may also be configured to disregard if the results based on the different heart rate signal indicate that there is no need for haemodynamic intervention.

In some embodiments, the device is configured to mitigate for oversensing by the heart rate sensor. This may be done by determining whether the determined magnitude of the perfusion signal deviates from a benchmark measure, if it does deviate, modifying the oscillation period of the heart rate signal used to determine the magnitude of the perfusion signal, and determining a new magnitude of the perfusion signal.

The device may comprise a controller for outputting a signal to an implantable or externally wearable device for haemodynamic intervention based on the determined haemodynamic state of an individual.

The haemodynamic intervention may treat cardiac arrhythmia.
The device may comprise a controller for outputting a signal to a device for haemodynamic intervention in response to the determined haemodynamic state of an individual. For example, the device may be configured to output a signal to control the device for haemodynamic intervention based on the determined magnitude of the perfusion signal. The device may be configured to output a signal to modify the settings of the device for haemodynamic intervention, for example, where the device for haemodynamic intervention is a pacemaker to alter the AV (atrioventricular) and/or VV (ventriculo-ventricular) delays.

According to another aspect of the present invention there is provided a control system for haemodynamic intervention comprising a device as described above and the device for haemodynamic intervention, wherein the controller is configured to output a signal to control the device for haemodynamic intervention based on the determined magnitude of the first signal.

According to another aspect of the present invention there is provided a control system for haemodynamic intervention comprising a device as described above and an implantable device, wherein the controller is configured to output a signal to activate the implantable device when a magnitude of the heart rate signal is above a first threshold value and a magnitude of the first signal is below a second threshold value.

According to another aspect of the present invention there is provided a control system for haemodynamic intervention comprising a device as described above and a device for haemodynamic intervention, wherein the controller is configured to output a signal to activate the device for haemodynamic intervention when a magnitude of the heart rate signal is above a first threshold value and a magnitude of the first signal is below a second threshold value.

In an embodiment, the first signal is a perfusion signal. Different first and second threshold values may be used depending on the location at which the perfusion signal sensor is placed on or within the body.

The device for haemodynamic intervention may be a defibrillator device. In the system, the device may be an implantable device, for example, an implantable cardioverter defibrillator. The implantable device may alternatively be a pacemaker device for
example a Cardiac Resynchronisation Therapy (CRT) device. The device may be an externally wearable device, for example an externally wearable defibrillator device such as a "LifeVest™" device.

The device and the device for haemodynamic intervention may be integrated or separate. One or more sensors may be integrated with the device and/or the device for haemodynamic intervention.

In the system, the multiple frames of the perfusion signal may be collected over a predetermined time period. This time period may be programmable, such that the predetermined time period may be chosen or adjusted by the user. The predetermined time period may be set as the charge time of the device for haemodynamic intervention. The predetermined time period may be set to be prior to charging of the device. Monitoring during the device for haemodynamic intervention charge time may maximise the available data before a decision for therapy to be delivered. It is desirable to collect the haemodynamic information before charging, as charging drains the device battery.

According to another aspect of the invention, there is provided a method for determining a haemodynamic state of an individual from a magnitude of a first signal, wherein the first signal is a perfusion signal or a signal which is a measure of a volume of blood in the thoracic cavity, wherein the method comprises the steps of: receiving the first signal and a signal representative of the heart rate from the individual; dividing the first signal into frames, wherein a frame length is determined from an oscillation period of the heart rate signal; and determining a magnitude of the first signal from at least two frames.

In an embodiment, the first signal is a perfusion signal.

In the method, at least two frames of the divided perfusion signal may be combined.

In the method, the magnitude of the perfusion signal may be found as amplitude of the combined perfusion signal.
In the method the perfusion signal may be standardized prior to combining at least two frames of the perfusion signal.

In the method, the frame length may be determined from an average oscillation period of the heart rate signal.

In the method, a confidence measure value, which indicates the similarity of the divided perfusion signals in different frames that have been combined, may be output.

In the method, a multiple number of perfusion signals may be received and a magnitude of each perfusion signal from at least two frames of the same perfusion signal may be found.

In the method, the perfusion signal may be associated with concurrently received heart rate signal.

According to another aspect of the present invention, there is provided a control method for outputting a signal to a device for haemodynamic intervention based on a haemodynamic state of an individual determined from a magnitude of a first signal as described above.

The device may be an implantable device, for example an implantable cardioverter defibrillator or a pacemaker device. Alternatively, the device may be an externally wearable device, for example an externally wearable defibrillator device such as a "LifeVest™" device.

According to another aspect of the present invention, there is provided a computer storage medium comprising code for execution by a processor, the code, when executed by a processor causing the processor to perform the methods described above.

BRIEF DESCRIPTION OF THE DRAWINGS
13

Figure 1 is an example illustrating the information which can be represented by different physiological parameters;

Figure 2 is a function block diagram of a control device system according to an embodiment of the present invention;

Figure 3 is a flow diagram illustrating the perfusion signal processing steps according to an embodiment of the present invention;

Figure 4 is a schematic illustration of the perfusion signal processing steps according to an embodiment of the present invention;

Figure 5 is an example comparing perfusion signal processing according to different methods;

Figure 6 is another example comparing perfusion signal processing according to different methods; and

Figure 7 is a flow diagram illustrating the algorithm used by a therapy guide decision maker according to an embodiment of the present invention.

DETAILED DESCRIPTION

Many current implantable or externally wearable devices monitor and/or deliver therapies for treating disorders of the cardiac rhythm based on electrical information obtained from the electrical changes that are sensed from the heart. Such electrical activity of the heart represents the heartbeat, but relying solely on this information may not be sufficient to guide therapy reliably as mentioned above.

Any misguidance of therapy can be particularly harmful where the device is an implantable or externally wearable cardiac defibrillator device which delivers therapy for treating cardiac arrhythmias, because it involves delivering a rapid sequence of electrical stimuli (overdrive pacing) or larger electric shocks (defibrillation) to the heart in an attempt to restore the heart to a normal rhythm. Overdrive pacing can be harmful because sometimes it causes the tachycardia to deteriorate into a faster tachycardia which can worsen the function of the heart. Electric shocks can be extremely painful to the individual if delivered while the individual is conscious. Whilst the present invention would be advantageous when used with the application of any of the mentioned implantable or externally wearable devices, it is particularly useful when used in combination with an implantable or externally wearable defibrillator device, as
delivering such high level shock to the heart due to misguidance of the data received is more detrimental than if a lower level impulses are applied as a result of a misguidance.

In the case where the implantable or externally wearable device is an ICD, for example, electrical noise from a damaged lead or sensor may be indistinguishable from the electrical signal of a pathological rhythm such as ventricular fibrillation (VF). The ICD lead or sensor may be damaged from, for example, a fracture. Such noise cause by the damaged ICD lead or sensor may be incorrectly interpreted as an arrhythmia and the device may inappropriately deliver a therapy that is harmful in this situation. In the case where the device is an externally wearable defibrillator, similar problems with noise causing inappropriate shocks can occur. Similarly, the tolerability of various tachyarrhythmias varies between individuals. It is advantageous to guide therapy delivery using the patient's haemodynamic status during these real or presumed dysrhythmias, as the haemodynamic information can be used to prevent shocks being delivered in the absence of an arrhythmia. In response to the detection of an apparent arrhythmia, the haemodynamic state of the individual is determined, again, with an alternative signal representative of the heart rate. If this determines that no intervention is required, then it is an indication that the lead or sensor is damaged. Devices implanted to prevent vasovagal syncope may also benefit from having a haemodynamic signal to guide treatment.

In addition, the use of haemodynamic state in conjunction with the heart rate signal may be advantageous in that there may be situations wherein it is difficult to distinguish whether a therapy should be delivered or not. For example, there may be a case where heart rate increases for reasons that are not a tachyarrhythmia that requires therapy. A common example is when a patient is engaged in physical activity and the heart rate increases through the normal control systems of the body.

In tachyarrhythmias requiring treatment, the electrical activations of the heart are generally activating the muscle cells of the various regions of the heart occur in an abnormal sequence, which causes the effectiveness of the heart as a pump to be lower than it otherwise would be, even at the same heart rate. Therefore, it is important to be able to distinguish between the situation of the heart rate increasing through normal processes, where the pumping efficiency of the heart is better, versus, the situation of the heart rate increasing through abnormal processes (ventricular tachycardia), where
the pumping efficiency of the heart is worse. This distinction cannot be accurately
made solely on the heart rate.

As such, guidance as to whether a therapy should be delivered to the heart only based
on heart rate is not reliable. As it is nevertheless true that cardiac electrical signals
provide useful information, the cardio electrical signal may be used in combination with
the perfusion signal to determine whether or not a therapy should be delivered.

As previously mentioned, known methods of quantifying the perfusion data rely on an
assessment of an absolute magnitude of the signal which is subjected to positional and
noise components. Firstly, it is very difficult to predict the exact positions of the peak
and the trough of the perfusion signal that have been caused by the heart. Secondly,
even if an assumption were to be made as to where the peak and the trough of the
perfusion signal may be, a measurement of an absolute magnitude of the signal at the
relevant points may not reflect the actual haemodynamic state, as noise components
may be included in the perfusion signal at the relevant position. Such a high noise
component which is present in a perfusion signal results in low reliability and hence
clinical utility of using the perfusion signal as a factor to consider when deciding
whether or not a therapy should be delivered by the device.

Referring to Figure 2, an embodiment of a control device system according to the
present invention is shown. The control device system comprises a controller
connected to an implantable or externally wearable device, a perfusion sensor and a
heart electrical activity sensor, wherein the controller is configured to activate the
implantable or externally wearable device according to the perfusion signal and the
heart electrical activity signal received from the respective sensors. For example, in this
embodiment, the implantable or externally wearable device is an ICD, the perfusion
sensor is a laser Doppler, and the heart electrical activity sensor is an ICD lead
connected to ICD. As the skilled reader will appreciate, it is not essential to measure
heart activity directly. Any signal that has the same wavelength as the heartbeat may
be used. The control device system may be integrated into a single implantable or
externally wearable device (e.g. including the controller and one or more sensors), or
only parts of the system may be integrated in the implantable or externally wearable
device. For example, the controller and the implantable or externally wearable device
may be integrated and the sensors may be separate devices that may not even be
implanted but obtain perfusion signal and the heart electrical activity signal externally. As such, the controller, the sensors and the implantable or externally wearable device may be electrically connected to each other or be wirelessly connected. The controller may be an external device, for example an externally wearable device, which may also be integrated with one or more sensors.

The controller comprises a perfusion signal processor and a therapy guide decision maker. The perfusion signal processor is configured to receive the perfusion signal obtained by the perfusion sensor, process the perfusion signal to quantify the signal and output a haemodynamic state value representative of a haemodynamic state of the individual to the therapy guide decision maker. For example, this haemodynamic state value could be between zero and one hundred, wherein zero represents no fluctuation (and no perfusion) in the haemodynamic state and a hundred represents a very large fluctuation (high perfusion level). The therapy guide decision maker is configured to receive the heart electrical activity signal which represents heart rate of the individual and the haemodynamic state value from the perfusion signal processor and make a decision based on the information received as to whether to output a signal for activating the implantable or externally wearable device or not.

The implantable or externally wearable device may be an implantable cardioverter defibrillator (ICD), an externally wearable defibrillator, a pacemaker or a nerve stimulator. The pacemaker may be a CRT device, which is a type of pacemaker having an extra lead to pace not only the right, but also the left ventricle. A CRT device may be used for patients with heart failure for example.

An example of an externally wearable defibrillator is a "LifeVest™" device. An externally wearable defibrillator may comprise two or more pads which, when the device is worn, contact the skin at appropriate locations on the chest area, each pad comprising an electrode. It may also comprise a small battery pack, which may be worn separately but connected to the pads, for example on a belt. It may also comprise a perfusion sensor and/or a heart electrical activity sensor and/or the controller. The haemodynamic sensor or perfusion signal sensor (for example laser Doppler sensor) may thus also be wearable and integrated with the externally wearable device; or may be wearable and not integrated (for example as a watch or skin patch) and communicate with wired or wireless communication; or may be implanted (whilst the
defibrillator is externally wearable) and communicate wirelessly to the externally wearable device. Such devices may be worn by people at risk of cardiac death who are waiting for an implantable device for example. In externally wearable defibrillator devices, similar problems as described above, where noise can cause inappropriate shocks, can occur.

The system may thus comprise any combination of an implantable or externally wearable device for haemodynamic intervention, together with an integrated or non-integrated and implantable or externally wearable perfusion signal sensor, an integrated or non-integrated and implantable or externally wearable heart rate signal sensor, and an integrated or non-integrated and implantable or externally wearable control device.

Whilst any implantable or externally wearable device would benefit from incorporating haemodynamic status determined from the perfusion signal processor of the present invention, the benefit may be particularly significant in the case where the implantable or externally wearable device is a defibrillator, as discussed above.

The perfusion sensor and the heart electrical activity sensor are configured to receive tissue perfusion signal and heart electrical activity signal from an individual. The perfusion sensor can use a variety of methods to obtain tissue perfusion signals, such as laser Doppler, spectroscopy and ultrasound Doppler. The heart electrical activity sensor obtains signals that represent the individual's heartbeat.

As explained above, the problem with previously-known implantable or externally wearable devices which sense and process tissue perfusion signals is that they are prone to being affected by high noise components hence limiting their reliability and clinical utility. In order to overcome the problem, the perfusion signal processor according to the present invention isolates the amplitude of cyclical oscillations in tissue perfusion that correspond to the cyclical electrical activation of the heart, by processing the perfusion signal based on the electrical activation oscillation period. With reference to Figure 1A, it can be seen that the perfusion signal pulsates in synchrony (even if there is a delay or a shift) with a single heartbeat. This relationship between an oscillation period of the perfusion signal and an oscillation period of the cardiac electrical signal is used to process the perfusion signal solely in a time domain.
In essence, the perfusion signal is divided up into frames that have their length based on the oscillation period of the cardiac electrical signal. Then, at least two of the perfusion signal frames are overlapped in the sense that an average signal is outputted from the at least two perfusion signal frames. The basic principle behind this is that as the perfusion signal pulsates in accordance with the heartbeat, which is represented by the oscillation period of the cardiac electrical signal, the parts of the signal that are pulsating according to the heartbeat are averaged and any parts of the signal that are simply noise and hence not pulsating are destructively combined such that any noise components are naturally disregarded. Therefore, an amplitude of the combined perfusion signal frames is considered to be a reliable representation of the haemodynamic state of the individual. This process is illustrated as a flow diagram of Figure 3, and described in more detail with reference to Figure 4 below.

The perfusion signal processor is configured to process the perfusion signal received according to the following steps, which are described with reference to Figures 3 and 4. Figure 4 is a schematic illustration of the perfusion signal processing steps as described in the flow diagram of Figure 3. The flow diagram of Figure 3 starts with step 301 of receiving a perfusion signal and a heart rate signal. Note that a cardiac electrical signal such as an ECG signal is considered to represent the heart rate of the individual, and the three terms may be used interchangeably. As can be seen in Figure 4, stages 1.1 and 1.2, ECG signal and raw perfusion signal are made available to the control device according to this embodiment of the present invention. The sampling frequency of the perfusion data should be at least double the cardiac cycle and preferably will exceed this. For example, at a typical heart rate of 120 beat per minute, the sampling frequency should exceed at least 4Hz. A sampling rate of up to around 100Hz or even higher (if memory allows) may be used. The minimum sampling frequency is related to the fact that the present invention utilises the relationship between the cyclical electrical activity in the heart and the resultant oscillations in the tissue perfusion signal. If the tissue perfusion signal is sampled at less than double the frequency of the oscillations, interpretation becomes ambiguous. Therefore, the minimum sampling rate is dictated according to the Nyquist theorem.

The next step of the flow diagram of Figure 3, step 302, is to calculate frame length from an oscillation period of the heart rate signal. This is illustrated in Figure 4 as stage 2, wherein the R waves in the ECG signal have been marked with a dot. In this
embodiment, the R waves are used to mark the interval between successive cardiac cycles (i.e. R-R interval in this case) to determine the frame length of the perfusion signal. In other words, a frame length is calculated as the time period between a detected R wave and a successively detected R wave, which is essentially an R-R interval. Therefore, a perfusion signal frame is a segment of the perfusion signal which has been extracted from the original perfusion signal over a time period equivalent to the frame length. To the skilled reader, it is evident that the electrical signal could be acquired from a lead in the atrium of the heart, rather than the ventricle of the heart. When a lead is in the atrium, the signal corresponds to the timing of atrial activation which on the 12-lead ECG is described as the P wave. The skilled reader will see that these timing signals, which are essentially the P-P interval, can be used in the same way as those of the R-R interval. Therefore, in this disclosure, the terms R wave and R-R interval should be understood to also cover the possibility of the P wave and P-P interval.

In other embodiments, the frame length may be determined based on the R-R interval of the particular heartbeat, obtained from an electrical signal from the atrial lead, which is simultaneous with the perfusion signal frame (or the perfusion signal frame portion of the perfusion signal) and therefore vary throughout the analysis period. This may be done in the case of Atrial Fibrillation (AF) or patients with frequent Ectopic beats for example. In this case, the resultant perfusion signal frames are resampled to a standardised frame length. In other words, since each perfusion signal frame length may vary, the perfusion signal frames are adjusted to have a single frame length. Thus if different frame lengths are possible, the frames of the perfusion signal can be modified before summation so that they are all of the same length. This may be done by stretching or by interpolation for example.

Optionally, frames of the perfusion signal which deviate in length significantly from a benchmark may be excluded from the summation. Thus, the device may be configured to perform a step of determining whether the frame length deviates before the summation, and if it is found to deviate, excluding the frame from the summation. For example, all frames for which the length deviates by greater than a threshold amount from the benchmark may be excluded. For example, all frames which deviate from the benchmark RR interval by an amount greater than or equal to 25% of the benchmark interval may be excluded, or all frames which deviate by more than 100ms. The
benchmark may be a mean, median or modal length for example. Alternatively, the exclusion may be performed by reference to the standard deviation or other measures. Thus during AF or any condition for which there is an irregular heart rate rhythm, the device may determine the exclusion of particularly short or particularly long R-R intervals, this being determined with reference to the mean or standard deviation or other measures.

In yet another embodiment, an average R-R interval length may be found over several heartbeats and used as the frame length.

It should be noted that any other fiducial marker and its associated interval (which is the length between successive detection of the chosen fiducial marker) may be used to define the frame length. It is often preferable to use the R waves, as they are the most predominant in an ECG signal.

In some embodiments, the perfusion signal may be smoothed using various methods, prior to dividing the perfusion signal up into frames. Such smoothing techniques include using an algorithm such as band pass filter or Savitzky-Golay filters. Such filters may remove high frequency noise such as those associated with electrical noise or muscle activity and low frequency oscillations such as those associated with respiratory activity. Oscillations within the physiological and pathological heart rates (typically between 0.5Hz to 5Hz) should not be filtered out. Such a step of filtering is illustrated as step 303 in the flow diagram of Figure 3, and as stage 3 in Figure 4 shows as stage 3, wherein the perfusion signal is smoothed using a band pass filter.

The next step, step 304, of the flow diagram in Figure 3 is to divide and extract the perfusion signal in the frame length derived from the ECG signal. In essence, the perfusion signal is divided up into a frame of the length calculated from an oscillation cycle of the ECG signal. In this way, a peak and a trough that has been caused by a heartbeat, which is represented by the oscillation period of the cardiac electrical signal, will be contained in this frame. This is because there is a direct relationship between the oscillation period of the ECG signal and the perfusion signal. In this embodiment, the oscillation period is the same for the ECG signal and the perfusion signal. This can be seen from the ECG signal and the perfusion signal illustrated in Figure 4, wherein
the perfusion signal pulsates with the same period of oscillation as the ECG signal (in some cases there may be a delay or a shift). As such, dividing the perfusion signal up by the oscillation period of the ECG signal ensures that a single pulse comprising a peak and a trough that have been caused by the cardiac activity (and not noise) is included in each perfusion frame.

In the embodiment illustrated in stage 4 of Figure 4, the perfusion signal frame starts at the time corresponding to the R-R interval. Stage 4 of Figure 4 depicts the perfusion signal being divided up with the vertical lines that have been applied to the perfusion signal, wherein each vertical line corresponds with an R wave of the ECG in position on the horizontal axis, which represents time. Each pair of consecutive vertical lines may be considered to define a window which is applied to the perfusion signal to divide it up into perfusion signal frames. Here, it can be seen that the perfusion signal frame starts at the same position as the R-R interval as shown in the ECG signal.

In other embodiments, the windows may be applied slightly shifted in time, so as to account for the delay between the electrical activation of the heart and associated contraction and the corresponding increase in the tissue perfusion signal. Typically, the ECG signal and the perfusion signal are simultaneously acquired. However, there is a delay, or a slight shift, in the oscillatory cycle between the ECG signal and the perfusion signal. This delay is caused by the biological process by which the electrical activation of the heart causes the heart to contract and eject blood, which builds up a reservoir of excess blood in the large arteries, that then progressively flows through the smaller vessels, which are typically the ones detected by the sensor. Such biological delay is typically much larger than any electrical or computational delay inside the sensors that provide the perfusion signal. This biological delay is generally in the order of around 300 to 700ms. On average this can be considered as around half a cardiac cycle and hence the window may start preceding the R wave by a fraction of the cardiac cycle such as 50%. The shift value may be fixed or customised for each individual.

Advantageously, the shift value may be selected so that the position where the midpoint of the pulse in the perfusion signal caused by the activation of the heart is centred in the window (and hence centred in the perfusion signal frame). Alternatively, the shift value may be selected so that the nadir (or start of the upstroke) of the
perfusion signal aligns with the start of the window. The skilled reader will understand that it may not be possible to identify the exact peak or trough that has been caused by the electrical activation of the heart, but that it is nevertheless possible to predict whereabouts such peak and trough should be based on the general relationship between the electrical activation of the heart and the perfusion signal, and hence position the window accordingly. In view of this, the window length calculated from the ECG signal may be applied to the perfusion signal shifted by a predetermined value.

A step of correcting for any mismatch between the phase of the perfusion signal and the phase of the heart rate signal may thus be performed. This may improve coherency. This correction may comprise first detecting an R wave in the heart rate signal, then finding the next nadir (i.e. minimum) in the perfusion signal after the time point corresponding to the R-wave. The minimum can be found from a smoothed perfusion signal for example. This is the first nadir after the R wave. Electrical activity (i.e. the R wave) generally occurs a few ms prior to mechanical activity in the heart, which in turn occurs a few hundred ms before the termination of the downslow of the diastolic decay of flow/pressure (i.e. lowest point before an upstroke). The time difference between the nadir in the perfusion signal and the corresponding R wave in the ECG signal is then determined. The perfusion signal is then segmented in line with the location of the R wave plus a fixed interval, the fixed interval being calculated from the delay. In other words, the beginning of each segmentation window is located at the time point on the perfusion signal corresponding to the location of the corresponding R-wave plus the fixed interval. The end-point of the segmentation window is located a length of time after the beginning location of the window, the length of time corresponding to the duration between the R-wave and the subsequent R-wave. In the above described case, the perfusion signal and the ECG signal are aligned at the “up-sloping portion” of the perfusion signal. However, alternatively they may be aligned at the peak or at other fiducial points (such as maximum slope).

Even if the window has been applied in such a way that a perfusion signal frame contains a part of the perfusion signal pulse (e.g. 40%) that is caused by a previous cardiac activity and a part of the consecutive perfusion signal pulse that is caused by the following cardiac activity, this does not have a significant effect on the final haemodynamic state value calculated. This is because each perfusion signal frame would still overall contain a single pulse with one true peak and one true trough each
caused by the cardiac activity at the same positions, such that the peaks and the troughs nevertheless line up positionally when grouped and averaged.

Once perfusion signal frames are obtained, the next step is to find an average perfusion signal frame based on at least two perfusion signal frames, as described in step 305 of the flow diagram of Figure 3. This step is illustrated as stage 5 in Figure 4, wherein ten perfusion signal frames are grouped together and averaged. Whilst ten perfusion signal frames are used in this example, it will be appreciated that other number of perfusion signal frames may be used, as long as more than two perfusion signal frames are used. Typically, around 2 to 50 perfusion signal frames are used. More preferably, around 5 to 20 perfusion signal frames are used. The preferred method analyses 10 to 20 heart beats which translates to around 6 seconds. This time period is short enough that any drift of the signals over time would be irrelevant. A minimum of two perfusion signal frames must be used, so that the true oscillation which has been caused by the cardiac activity can be identified and any fluctuations caused by noise disregarded. Only the true fluctuations that are caused by the cardiac activity, which therefore has the same period as the oscillation of the ECG signal, line up when the perfusion signal frames are grouped together, as in stage 5 of Figure 4.

Any fluctuations that are caused by noise are not in phase with the oscillation period of the ECG signal and hence do not line up when the perfusion signal frames are grouped together. As such, when the perfusion signal frames are grouped together and averaged, the noise that does not pulsate according to the cardiac activities combines destructively such that the noise components of the perfusion signal frames are naturally disregarded. The perfusion signal frames may be combined by using many different methods known to those skilled in the art. These methods include finding the mean, median, or Winsorised mean. Prior to combining the signals in this way, the perfusion signal frames may be standardized by any well-known methods including subtraction of the mean or performing linear regression then subtracting the result of the linear regression. As the perfusion signal has been divided into the frames according to the oscillation period of the cardiac electrical signal, the fluctuations in the perfusion signal frames that are caused by the cardiac activity match up in position (in the time domain, position meaning position in the axis representing time). Any fluctuations that are mere noise components do not match up and hence when the
perfusion signal frames are combined, any noise components are naturally disregarded. The noise components can be considered as being combined in a destructive manner.

In some embodiments, the combined multiple perfusion signal frame may again be smoothed by filtering using various different methods, including band pass filter or Savitzky-Golay filter.

A magnitude of the oscillation in the combined multiple perfusion signal frame is then found, as described in step 306 of the flow diagram of Figure 3. Such magnitude may be calculated using one of many methods known in the art, such as the range of the data, the standard deviation, or interquartile range. In the embodiment illustrated in stage 6 of Figure 4 an amplitude of the averaged perfusion signal frames (i.e. the combined multiple perfusion signal frame) is found by detecting the peak and the trough in the combined perfusion signal frame, and measuring the amplitude. An amplitude is an example of a magnitude of the oscillation in the combined multiple perfusion signal frames. Magnitude of the oscillation in the combined multiple perfusion signal frames could also include, for example, the integrated area of the combined multiple perfusion signal frames. Such an amplitude or a magnitude found by other methods discussed above is considered to be a representation of the haemodynamic state. In other embodiments, another magnitude such as an integration of the averaged perfusion frames may be considered. Before the magnitude is found, the combined perfusion signal frames may be checked to confirm that there is a single significant peak and a single trough. Depending on the location and positioning of the haemodynamic sensor in reference to the heart, dicrotic notch (which indicates the pressure increase upon closure of the aortic valve) may be detected, such that two peaks are obtained. However, the dicrotic notch is smaller in magnitude and it can be determined whether there is a single significant peak when two peaks are detected, by comparing the magnitude of the two peaks. If more than one peak (or more than one significant peak where two peaks are detected) or more than one trough is detected, the combined perfusion signal frames are discarded, or is assumed that the perfusion level is around zero such that only noise components remain in the perfusion signal.

Such magnitude of the oscillation of the combined perfusion signal frame is considered to represent the true haemodynamic state of an individual, as the combined perfusion
signal frame oscillates with the same period as the electrical cardiac cycle (even if there is a slight phase shift). This is because, as mentioned above, any peaks or troughs that were present at the frequency that does not correspond to the cardiac electrical cycle are discarded through the combining step. Furthermore, by considering the magnitude of the oscillation rather than an absolute value at a certain point, a more reliable value can be obtained. For example, the magnitude found for each perfusion signal frame may be converted into a value that is relative to the magnitude of the averaged signal, such as the mean or median, as changes in position or the volume of tissue under consideration under the same physiological conditions tend to scale up or down the signal and the amplitude of the oscillations in similar proportion. Such a value may also be calculated by considering the signal on a logarithmic scale. Therefore, any change in the absolute value of the perfusion signal which may occur due to such scaling up or down does not severely affect the overall magnitude value of the oscillation.

In some embodiments, multiple tissue perfusion signals may be obtained and used to calculate a final assessment of the haemodynamic state. For example, there may be two perfusion sensors. One may be incorporated onto the surface of an implantable device which sits under the skin. The other could be incorporated into a pacing lead which sits in the blood stream (these examples are not exclusive). If, for example the first sensor reports a low value (such as 1), and the other a high value (such as 10), then the invention could use the average of these two numbers, i.e. 5.5, as the final assessment of the haemodynamic state. In an alternative embodiment the invention could take the highest of these numbers, namely 10, as the final assessment of the haemodynamic state. As the method of the present invention quantifies the haemodynamic state from tissue perfusion by considering the association between the electrical activity of the heart and the pulsatile nature of the tissue perfusion signal, it is not readily affected by noise and the input from multiple tissue perfusion signals can be combined from simply selecting the maximum obtained.

The final step of the perfusion signal processor is to output the haemodynamic state value to the therapy guide decision maker, as in step 307 of the flow diagram of Figure 3. In this embodiment, the perfusion signal processor continuously outputs a haemodynamic state value calculated for a predetermined analysis period. Therefore, a
series of haemodynamic state values are output to the therapy guide decision maker over time. Where the haemodynamic values are output in this manner, the haemodynamic state of the person may be continuously monitored, and the ECG signal and the haemodynamic state values may be compared to check that the ECG signal, particularly when it indicates sinus rhythm, does not contain error. In other embodiments, a haemodynamic value may be output only when requested by the therapy guide decision maker.

In some embodiments, the perfusion signal processor may also output a confidence measure of the result. Such confidence measure may be calculated based on the similarity of the individual perfusion signal frames, using various different methods including correlation coefficient, standard deviation from the mean of the combined frame, concordance of the sign of the signal after subtraction of the mean and many more.

In some embodiments, the device is configured to mitigate for oversensing of the heart rate sensor. This may be done by determining whether the determined magnitude of the perfusion signal deviates below a benchmark (e.g. an expected value or range), modifying the oscillation period of the heart rate signal used to determine the magnitude of the perfusion signal, and determining a new magnitude of the perfusion signal. ICDs and other sensing devices may experience problems with oversensing in relation to the heart rate signal. In some sensing devices, after a sensed R wave is detected, there is a short blanking period when further electrical activity is not sensed, then a period of automatic gain control whilst sensitivity returns to a baseline before the next R wave. However, electrical signals that are sensed after the blanking period, in the automatic gain control period, may be included in the heart rate calculations, i.e. are incorrectly sensed as R waves, and therefore incorrectly raise the measured heart rate. This could occur if the QRS is broad, for example for a bundle branch block patient, or if the T waves are very prominent and are therefore detected as R-waves (leading to a measured heart rate value of double the actual heart rate value). This means that the measured heart rate may be higher than the actual heart rate, meaning that an incorrect, low perfusion value may be returned, prompting an unnecessary shock to be given. For example, if the heart rate determined from the heart rate signal is incorrectly measured as twice the actual rate, then half of the segments of the perfusion signal will comprise just a trough part, and half will comprise just the peak
part. When combined, these will cancel, and an artificially low perfusion value is determined.

To mitigate this effect, the device may be configured to determine whether the determined perfusion value is low (e.g. is below a threshold value, for example more than 2 or 3 percent less than the acceptable value). If it is determined that the perfusion value is low, the original perfusion signal is then segmented again using a heart rate signal (e.g. an electrogram (EGM)) for which some of the presumptive R waves are omitted. This may be done by excluding alternate R waves, or by calculating the intervals between groups of sensed R waves, looking for clusters of similar R-R intervals and then selecting the R waves that fit to this cluster of R-R intervals for example. A new perfusion value is then determined. Alternatively, the original heart rate signal may be re-analysed to detect the heart rate, using a different gain or different blanking window, i.e. the original R-wave detection algorithm can be modified, and a new perfusion value returned.

If the new perfusion value is within an acceptable range, then a shock is avoided. If not, the shock is then given. This step allows the device to check if an alternative interpretation of the heart rate shows electro-mechanical synchrony. If the alternative heart rate is correct, an acceptable perfusion value is returned if the patient is well and no shock is given. If the patient is unwell, the perfusion value will be low with any heart rate, therefore it is appropriate for the device to give a shock.

It was mentioned earlier that prior art methods of perfusion signal processing methods may sometimes provide an inaccurate representation of the true haemodynamic state of the individual. Figures 5 and 6 illustrate the differences between the known methods of perfusion signal processing and the perfusion signal processing according to the present invention.

Figure 6 illustrates an exemplary case where an individual goes into VT and the blood pressure reduces significantly. Unlike the blood pressure signal, it can be seen that the perfusion signal is much noisier than the blood pressure signal. The first method (method A) compared against the method according to the present invention uses a mean absolute value of the perfusion signal. In this case, similarly to the significant
drop of the blood pressure, there is also a significant drop in the general absolute
values of the perfusion signal, the use of calculating a mean absolute value of the
perfusion signal does indicate an appropriate fall in the absolute mean value over
certain amount of time period. However, the perfusion signal needs to be monitored
over a relatively long period in order to detect such a fall in the mean value, and to
account for random fluctuations over time in the local perfusion signal. This is to say,
the method relies on data from preceding intervals and bases the interpretation of local
perfusion data on an assessment of its absolute magnitude over time. This requires
extended periods of acquisition of perfusion data and increases energy consumption of
the controller. Furthermore, even with more perfusion data acquired over a longer
periods than that of the present invention, the decrease in the perfusion signal (and
hence the haemodynamic state) is not as clear as when calculated according to the
present invention. When the method of the present invention is used, most of the noisy
signals during fast ventricular rhythm are disregarded, as these signals simply do not
oscillate according to the oscillation of the ECG. Therefore, most of the noise signals
are cancelled out, and the result is the significant contrast of the perfusion signal
oscillation magnitude during sinus rhythm and fast ventricular rhythm. The second
method (method B) compared against the method according to the present invention
uses band pass filtering of the perfusion signal. In this case, the filtering method is
unsuccessful and is unable to remove the oscillation that was in fact due to noise. This
method is particularly weak where the noise component is in the form of a fluctuation
with some oscillatory behaviour, as it is difficult to distinguish such noise signal from a
true perfusion signal which also pulses. As such, the amplitude of the oscillation due to
noise is still calculated and hence the significant decrease in the perfusion signal is not
reflected in the values representing haemodynamic state found using the second
method. As noted previously, even the noisy signals that occur with some oscillatory
behaviour are disregarded when the present method is used, because these noise
signals do not line up with the ECG oscillations.

Figure 5 illustrates an exemplary case where the individual goes into VT and the blood
pressure falls greatly. In this case, however, the absolute perfusion signal values
actually rise despite the fact that the blood pressure drops and the relative perfusion
signal magnitude also drops in comparison to when in sinus rhythm (which may occur
due to small shifts in sensor position or orientation). As in the case illustrated with
reference to Figure 6, the first method (method A) using the absolute mean value and
the second method (method B) using band pass filter are compared against the
method according to the present invention. Due to the increase in the absolute values
of the perfusion signal, the absolute mean value of the perfusion signal is calculated as
having increased. Therefore the first method fails to detect the blood pressure fall and
hence fails to determine the true haemodynamic state of the individual. The second
method again does indicate some fall but not one which is as significant as the one
found using the present invention. The oscillations due to noise signal have not been
removed using the band pass filter, such that the fall is detected but the severity of the
situation is not represented as clearly in the haemodynamic values output from the
method. The perfusion signal processing method according to the present invention
calculates the amplitude of the noise fluctuation as being very low in this case also.

As can be seen above, the perfusion signal processing according to the present
invention outputs reliable values even in cases where other methods may fail to output
reliable values indicating the true haemodynamic state of the individual.

As such, it can be seen that even after filtering, removal of artefacts, or noise
suppression, quantifying based on an absolute magnitude or magnitude in respect to a
reference state may result in an inaccurate representation of the true haemodynamic
state of the individual. In contrast, when the perfusion signal is processed according to
the present invention, perfusion signal can be quantified to represent a true
haemodynamic state even in the presence of noise and artefact by utilising the
relationship between the cyclical oscillations in the tissue perfusion signal and the
cyclical electrical activity of the heart.

As illustrated above, in the method according to the present invention it is not
necessary to obtain data over a long period of time, which is required for other methods.
Therefore, it is not necessary for large amounts of memory or power to be provided in
order to store data over a protracted period. In one embodiment, a history of data
during an episode of cardiac arrhythmia or for a series of different episodes of cardiac
arrhythmia may be stored in memory for future analysis or comparison against current
data. Furthermore, as the perfusion signal processing of the present invention is done
mainly in the time domain (whilst filtering in the frequency domain is used for improved
accuracy, the main inventive concept lies in processing in the time domain), the
perfusion signal data may be collected only over a short period of time, for example based on the charge time of the device so as to maximise the available data before a decision for therapy to be delivered. In other cases, the time may be varied to be based on a fixed number of cardiac cycles, or be based on an assessment of the consistency or quality of the derived signal. Furthermore, as the method is more robust to changes in sensor position and other fluctuations; the need to have data from immediately before the suspected arrhythmia is lessened as new value may be compared to a previously calculated results. In any case, the processing power requirement for the signal processing according to the present invention is significantly lower than those relying only on the frequency filtering.

When the therapy guide decision maker receives a reliable quantified value obtained from the perfusion signal which represents the haemodynamic state of an individual as described above, the value is determined as either high or low. The criteria for differentiating whether the value is high or low is based upon a predetermined threshold value. In other embodiments, the predetermined threshold value may be customizable or dynamic. This is to say, the threshold value may be based upon a database of values representing haemodynamic state during other electrical and haemodynamic circumstances of the individual, or other individuals. For example, the threshold value may be based on previous values obtained during the individual's routine activities, or determined during situations simulating the pathological states such as rapid ventricular pacing or induction of VT testing. The threshold value may also be selected based upon haemodynamic state values obtained during previous time periods and selected as a multiple/fraction of the values. For example, if in a particular patient during normal rhythm the range of values representing haemodynamic state are between 5 and 20, and in that particular patient VT (either spontaneously arising or mimicked using rapid ventricular pacing) produces a value of 2, then a suitable threshold to program might be 3 for tachycardias detected. When a tachycardia is detected the value of the haemodynamic state and would be evaluated.

If it were below 3 the device would proceed to provide therapy (for example, overdrive pacing or defibrillation). In this example, if the value of the haemodynamic state was instead much higher, at 7 or 8, the device may not provide therapy. Preferably, the device is pre-programmed with a threshold for therapy with the option of adjusting the threshold in light of clinical experience in that patient, or in light of newer developed modules for measuring haemodynamic status.
Referring back to Figure 2, it can be seen that the therapy guide decision maker of an embodiment according to the present invention is configured to receive cardiac electrical signal. As such, the cardiac electrical signal may be used to determine the condition of the individual initially, and the haemodynamic state value may be used in conjunction with the cardiac electrical signal to ensure: prevention of inappropriate therapies that may be caused by various the ECG signal errors; delay/prevent delivery of a therapy by the implantable or externally wearable device in case of haemodynamically stable cardiac rhythmic malfunction; and check whether the delivery of therapy by the implantable or externally wearable device has been successful. The algorithms used by the therapy guide decision maker of an embodiment according to the present invention are illustrated as a flow diagram in Figure 7. The therapy guide decision maker is configured to output a signal, which activates the implantable or externally wearable device to deliver a therapy, to the implantable or externally wearable device according to the outcome of the algorithm.

In the algorithm, in order to reduce the risk of delivering therapy inappropriately in circumstances where the patients are in a normal heart rhythm but there is an error in the ECG signal received, the device requests information from the hemodynamic sensor once a ventricular arrhythmia has been diagnosed using the ECG signal. This involves determining whether the ECG signal value obtained is higher or lower than a threshold value/range. Such condition depends on the implantable or externally wearable device. For example, in the case where the implantable device is an ICD, it is determined that the individual is having a VF where the ECG signal value is higher than a threshold value.

In an embodiment where the implantable or externally wearable device is a defibrillator, the activation signal from the device causes the defibrillator to deliver Anti-Tachycardia Pacing or a shock to treat the heart rhythm disturbance.

In another embodiment where the implantable or externally wearable device is a nerve stimulator, the activation signal from the device causes the nerve stimulator to deliver pulsation or deactivate pulsations which stimulate a branch of the autonomic nervous system to increase blood pressure through vasoconstriction.
In yet another embodiment where the implantable device is a pacemaker, the activation signal from the device causes the pacemaker to increase its pacing rate to prevent pre-syncope or syncope.

In another embodiment in which the implantable device is a pacemaker, the device, rather than using the ventricular lead which is either sensing true VF or electrical noise mimicking VF the device, should utilize the electrical activity from an atrial pacemaker lead or if present left ventricular pacemaker lead (in CRT devices) or His lead, to segment the tissue perfusion data and its further calculation as described above. If the individual is in a normal rhythm then the atrial electrical activity will be concordant with the tissue perfusion oscillations and the device interprets this as malfunction of the ventricular lead/sensor. If the individual is in ventricular fibrillation, as the potential random oscillations in the tissue perfusion signals will not line up with either the organized or disorganized atrial signals, this will then be interpreted as the patient is in VF and as such therapy will be initiated.

In some cases, leads or sensors for obtaining the cardiac electrical signal may be damaged and acquire a signal which is mixed with electrical noise that are indistinguishable from the actual cardiac electrical signal which represents the individual's cardiac activities. In such cases information extracted from the noise mixed signal may not validly represent the individual's actual condition. As such, it cannot be reliably determined whether a therapy should be delivered by the implantable or externally wearable device or not. The implantable or externally wearable device could regularly or continuously request data on the haemodynamic state using electrical information from other leads. By doing this, it is possible to regularly check for any errors that may be occurring in the ECG signals, as well as monitoring the individual's condition.

After the delivery of therapy the implantable or externally wearable device may request further data on the haemodynamic state to confirm improvement. The device may then utilise this information to confirm the successful interpretation of the pre-therapy data and/or therapy delivery.
In summary, tissue perfusion signals obtained from a variety of methods including laser Doppler, spectroscopy, ultrasound Doppler are interpreted with reference to the electrical activity from the heart to isolate the amplitude of cyclical oscillations in tissue perfusion that correspond to the cyclical electrical activation of the heart. The resultant value representing the haemodynamic state is interpreted with reference to predetermined or customised criteria to differentiate haemodynamic states. Whilst the example embodiment discussed in the specific description includes an ICD, it will be clear to the skilled person that the haemodynamic states information can be used by any other implantable or externally wearable device for treating cardiac arrhythmia such as a pacemaker or a nerve stimulator to guide therapy delivery. The addition of this information on haemodynamic status to ICD or external defibrillator algorithms deciding therapy delivery is particularly advantageous as it would be expected to reduce the number of shocks an ICD or external defibrillator device needs to deliver during a time when a high rate of electrical signals is observed. This high rate could be due to ventricular tachycardia or due to noise. Electrical dysrhythmias and would also allow the assessment of the impact of therapies aimed at reducing the detrimental impact of VT on cardiac output. The skilled person will appreciate that the use of haemodynamic state reliably extracted by a controller according to the present invention may also be particularly advantageous when used in conjunction with any implantable or externally wearable devices for treating cardiac arrhythmia.

By using the perfusion signal processing as described above, it will be appreciated by the skilled person that it is possible to obtain a reliable value representative of the true haemodynamic status. Therefore, using this value, it is possible for the therapy guide decision maker to determine whether a therapy should be delivered by the implantable or externally wearable device or not in a more reliable manner.

The control device of the present invention may be incorporated into any existing cardiac therapy guide modules. For example, it could be integrated with an implantable or externally wearable device, or be integrated with a haemodynamic state monitor or a perfusion signal sensor so that the sensor can output a value representing a haemodynamic state from the perfusion signal data obtained from the sensor itself.
Whilst many of the example embodiments above are described in relation to implantable or externally wearable cardiac devices, the device of the present invention may be incorporated into various other devices. In fact, the device of the present invention may be incorporated into any system which uses perfusion signal to determine a haemodynamic state of an individual.

In one embodiment, the device of the present invention may be adapted to monitoring local haemodynamic state and outputting the determined haemodynamic state for the user to view on a display. Such local haemodynamic state displayed is used for patients in whom there is concern about the degree of perfusion in different parts of the body. For example, an operation may involve moving a flap of tissue, connected to the circulation by just one artery. Over the next few hours and days after the operation, it is necessary to re-operate if the connection fails such that the tissue loses blood supply. Currently known methods for monitoring whether the connection (blood supply to the tissue) is lost involves a laser Doppler perfusion monitor which displays the trace of the perfusion signal as a graph, or a mean value representing the perfusion signal collected over a predetermined period of time. This would then be monitored by the user wherein it can be determined that the connection has failed if there is a drop in the graph or the value output. As discussed in detail above, raw perfusion signal is very noisy and currently known devices require for continuous human input for determining whether the connection is lost or not. By implementing a device according to the present invention for determining a haemodynamic state of the perfusion signal acquired, it is possible to obtain a much more reliable value which represents the actual haemodynamic state of the patient.

Furthermore, as the values representing the haemodynamic state are more reliable, it is possible to implement an algorithm which outputs a signal to alert the user when the haemodynamic state value decreases below a threshold value. As such, the device may simply display the haemodynamic state values obtained from the perfusion signal according to the present invention, or output a signal to notify the user when the haemodynamic state falls below a predetermined threshold value. In the latter case, the algorithm used is similar to when the device is connected to an implantable or externally wearable cardiac device, but it alerts the user rather than to activate an implantable or externally wearable cardiac device. In this embodiment, local haemodynamic state values are determined by using a number of different sensors in
different parts of the body. Each perfusion signal acquired from each sensor is processed separately, by dividing each signal into frames in accordance with an oscillation period of the heart rate signal then combining at least two frames of the same signal, such that a haemodynamic state value is obtained for each perfusion signal. Due to the perfusion signal processing method of the present invention, a graph of the haemodynamic state values obtained or the mean value output is more reliable than those output by the known devices.

In an embodiment, the device of the present invention is configured to output a signal to control the implantable or externally wearable device based on the determined magnitude of the perfusion signal. The device may be configured to output a signal to modify the settings of the implantable or externally wearable device, for example to optimise the AV (atrioventricular) and/or VV (ventriculo-ventricular) delays of pacemakers and/or Cardiac Resynchronisation Therapy (CRT) devices based on the determined magnitude of the perfusion signal. A method of optimising the AV (atrioventricular) and/or VV (ventriculo-ventricular) delays is described in WO 2006/008535, which is hereby incorporated by reference.

For example, a range of device settings may be applied (e.g. an AV delay of 40, 80, 120, 160, 200ms). At each setting, the magnitude of the perfusion signal is determined. The setting that gave the highest perfusion value would then be selected and a control signal sent to the device to select this setting. Alternatively, a graph of AV delay against perfusion value may be plotted, a curve fitted, and the setting corresponding to the highest point on the curve selected. VV delays settings may be varied from -50ms to +50ms for example and optimised in the same manner. All pacemakers can have AV optimisation, CRT devices can also have VV optimisation.

The device may therefore be adapted for optimisation of pacemaker settings. The normal settings of a pacemaker can be changed for patients, for example those with heart failure and those using Cardiac Resynchronisation Therapy pacemaker devices. These settings may be changed and the haemodynamic results measured by a haemodynamic sensor, which may measure the perfusion signal. A perfusion value may then be determined as has been described herein and used to determine the optimal setting.
In an embodiment, the determined magnitude of the perfusion signal can thus be used to determine the settings of the pacemaker, for example to determine the optimal settings for the delay between the atria and the ventricles or between the two ventricles. This could be done with an implanted device at regular intervals or using an external device for example. As has been described previously, the device may be integrated with the pacemaker, or separate. For example, an external perfusion signal sensor may be used on a patient with an existing implantable device to make a series of measurements in one session, change the settings of the implantable device in accordance with the perfusion values determined from the settings, and send the patient away. Alternatively, the sensor is integrated with the implantable device, or implanted or wearable, and the device can continuously make measurements as it tests the settings whilst the patient is at home, without intervention from the doctor.

Although the above methods and devices have been described in relation to a perfusion signal, a signal which is a measure of the volume of blood in the thoracic cavity can be used in place of the perfusion signal. For example, a lead impedance signal, which is a continuously generated measure of the impedance of the leads of an implantable device such as an ICD or a pacemaker and the portion of the heart tissue and thoracic cavity between the leads is a measure of the volume of blood in the thoracic cavity. A lead impedance signal varies with the heart beat on a beat by beat basis, reflecting the volume of blood within the assessed cardiac chamber. Pacemakers and ICDs which are known in the art are configured to intermittently measure the lead impedance. A continuous measurement of the lead impedance can be made in a similar manner. The signal which is a measure of the volume of blood in the thoracic cavity may be analysed in the same manner described above in relation to the perfusion signal.

While certain embodiments have been described, these embodiments have been presented by way of example only, and are not intended to limit the scope of the inventions. Indeed the novel methods and apparatus described herein may be embodied in a variety of other forms; furthermore, various omissions, substitutions and changes in the form of methods and apparatus described herein may be made without departing from the spirit of the inventions. The accompanying claims and their equivalents are intended to cover such forms of modifications as would fall within the scope and spirit of the inventions.
CLAIMS:

1. A device for determining a haemodynamic state of an individual from a magnitude of
a first signal, wherein the first signal is a perfusion signal or a signal which is a
measure of a volume of blood in the thoracic cavity of the individual, wherein the device
is configured to:
   receive the first signal and a signal representative of the heart rate from
   the individual;
   divide the first signal into frames, wherein a frame length is determined
   from an oscillation period of the heart rate signal; and
   determine a magnitude of the first signal from at least two frames.

2. A device according to claim 1, wherein the device is configured to combine at least
two frames of the divided first signal.

3. A device according to claim 2, wherein the magnitude of the first signal is found as
amplitude of the combined first signal.

4. A device according to claim 2 or 3, configured to standardize the first signal prior to
combining at least two frames of the first signal.

5. A device according to any preceding claim, wherein the frame length is determined
from an average oscillation period of the heart rate signal.

6. A device according to any one of claims 2 to 5, configured to output a confidence
measure value which indicates the similarity of the divided first signals in different
frames that have been combined.

7. A device according to any preceding claim, wherein the device is configured to
receive a multiple number of first signals and determine a magnitude of each first signal
from at least two frames of the same first signal.

8. A device according to any preceding claim, configured to associate the first signals
with concurrently received heart rate signal.
9. A device according to claim 8, configured to correct for any difference in phase between the heart rate signal and the first signal.

10. A device according to any preceding claim, comprising a controller for outputting a signal to a device for haemodynamic intervention in response to the determined haemodynamic state of an individual.

11. A control system for haemodynamic intervention comprising a device according to claim 10 and the device for haemodynamic intervention, wherein the controller is configured to output a signal to activate the device for haemodynamic intervention when a magnitude of the heart rate signal is above a first threshold value and a magnitude of the first signal is below a second threshold value.

12. The system according to claim 11, wherein the device for haemodynamic intervention is an implantable device or an externally wearable device.

13. A system according to claim 12, wherein the device is a defibrillator.

14. A system according to any preceding claim, wherein the first signal is a lead impedance signal.

15. A system according to any of claims 12 to 14, wherein the multiple frames of the first signal are collected over a predetermined time period.

16. A system according to claim 15, wherein the predetermined time period is a charge time of the device.

17. A method for determining a haemodynamic state of an individual from a magnitude of a first signal, wherein the first signal is a perfusion signal or a signal which is a measure of a volume of blood in the thoracic cavity of the individual, wherein the method comprises the steps of:

   receiving the first signal and a signal representative of the heart rate from the individual;

   dividing the first signal into frames, wherein a frame length is determined from an oscillation period of the heart rate signal; and
determining a magnitude of the first signal from at least two frames.

18. A method according to claim 17, wherein at least two frames of the divided first signal are combined.

19. A method according to claim 18, wherein the magnitude of the first signal is found as amplitude of the combined first signal.

20. A method according to claim 18 or 19, wherein the first signal is standardized prior to combining at least two frames of the first signal.

21. A method according to any one of claims 17 to 20, wherein the frame length is determined from an average oscillation period of the heart rate signal.

22. A method according to any one of claims 18 to 21, wherein a confidence measure value, which indicates the similarity of the divided first signals in different frames that have been combined, is output.

23. A method according to any one of claims 17 to 22, wherein a multiple number of first signals are received and a magnitude of each first signal from at least two frames of the same first signal is found.

24. A method according to any one of claims 17 to 23, wherein the first signal is associated with concurrently received heart rate signal.

25. A control method for outputting a signal to a device for haemodynamic intervention based on a haemodynamic state of an individual determined from a magnitude of a first signal according to claims 17 to 24.

26. A computer storage medium comprising code for execution by a processor, the code, when executed by a processor causing the processor to perform any of the methods of claims 17 to 25.
Haemodynamically tolerated VT caused systolic blood pressure to drop by only 24%, laser doppler oscillatory power remained above 2%

Haemodynamically non-tolerated VT caused systolic blood pressure to drop by 49%, laser doppler oscillatory power fell below 2%

**Fig. 1A**

**Fig. 1B**
301. Receive a perfusion signal and a heart rate signal

302. Calculate frame length from an oscillation period of the heart rate signal

303. Smooth and Band pass filter

304. Divide and extract the perfusion signal in the frame length calculated

305. Find an average perfusion signal frame based on at least two perfusion signal frames

306. Find a magnitude of the average perfusion signal, which represents a quantified haemodynamic state

307. Output the haemodynamic state value to the therapy guide decision maker

Fig. 3
ECG (available to device)
R wave indicated with dot
Stage 1.1: Receive ECG signal
Stage 2: calculate frame length
Blood Pressure
(not available to device)
Stage 1.2: Receive perfusion signal
Raw Perfusion Signal
(available to device)
Stage 3:
Smooth and Band pass filter
Stage 4:
Divide into frames using R wave of ECG
Stage 5: Perfusion signal frames grouped and averaged
Stage 6: Averaged perfusion signal frames peak-to-trough height measured

Fig. 4
**Fig. 5**

Blood pressure greatly reduced

The unfiltered laser perfusion signal

Mean does not fall so Method A fails to detect blood pressure fall.

Oscillations are still present in the band-passed perfusion signal

As the oscillations do not line up with the ECG, our method results in a very low signal
**Fig. 6**

**Blood pressure greatly reduced**

**The unfiltered laser perfusion signal**

**An appropriate fall in the mean perfusion signal**

**Oscillations are still present in the band-passed perfusion signal**

**As the oscillations do not line up with the ECG, our method results in a very low signal**
Receive the heart rate signal

Output a value representative of the current heart rate signal over a predetermined amount of time

Is the heart rate signal higher than a threshold value?

Request for a haemodynamic state value from the perfusion signal processor

Is the haemodynamic state value lower than a threshold value?

Output an activation signal to the implantable device for delivery of a therapy

Fig. 7
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61N1/39  A61N1/365  A61N1/37

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 2013/030307 A1 (RAJAN VINAYAKRISHNAN [NL] ET AL) 31 January 2013 (2013-01-31) abstract; figures 1,4,5,8-10 paragraphs [0014], [0019], [0051], [0065], [0067]</td>
<td>1-24</td>
</tr>
<tr>
<td>X</td>
<td>Wo 2012/096878 A2 (UNIV EAST CAROLINA [US]; FERGUSON THOMAS BRUCE JR [US]; HU XIN-HUA [US]) 19 July 2012 (2012-07-19) the whole document</td>
<td>1,17</td>
</tr>
</tbody>
</table>

X Further documents are listed in the continuation of Box C. X See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search 22 May 2017

Date of mailing of the international search report 06/06/2017

Name and mailing address of the ISA/Authorized officer

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel.: (+31-70) 340-2040, Fax: (+31-70) 340-3016

Pereda Cubián, David
## DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where applicable, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>
### International Search Report

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [x] Claims Nos.: 25, 26 because they relate to subject matter not required to be searched by this Authority, namely:

   Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

2. [ ] Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. [ ] Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] All required additional search fees were timely paid by the applicant, this international search report covers all searchable items.

2. [ ] As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- [ ] The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

- [ ] The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

- [ ] No protest accompanied the payment of additional search fees.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>US 2013030307  Al</td>
<td>31-01-2013</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td>US 2007060785  Al</td>
<td>15-03-2007</td>
<td>CN 101309722 A</td>
<td>19-11-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 102895002 A</td>
<td>30-01-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 102920587 A</td>
<td>13-02-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 102920588 A</td>
<td>13-02-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 102920589 A</td>
<td>13-02-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 3037127 Al</td>
<td>29-06-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 3040102 Al</td>
<td>06-07-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5292096 B2</td>
<td>18-09-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5770656 B2</td>
<td>26-08-2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5844725 B2</td>
<td>20-01-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5971872 B2</td>
<td>17-08-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 6034471 B2</td>
<td>30-11-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2009507609 A</td>
<td>26-02-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2012120872 A</td>
<td>28-06-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2013081798 A</td>
<td>09-05-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2014166581 A</td>
<td>11-09-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2014166582 A</td>
<td>11-09-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2015171579 A</td>
<td>01-10-2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2016047268 A</td>
<td>07-04-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2007060785 Al</td>
<td>15-03-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010160839 Al</td>
<td>24-06-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010221690 Al</td>
<td>02-09-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010221691 Al</td>
<td>02-09-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010222681 Al</td>
<td>02-09-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010222717 Al</td>
<td>02-09-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010222718 Al</td>
<td>02-09-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2016199252 Al</td>
<td>14-07-2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wo 2007033050 A2</td>
<td>22-03-2007</td>
</tr>
<tr>
<td>wo 2012096878  A2</td>
<td>19-07-2012</td>
<td>CA 2824134 Al</td>
<td>19-07-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2663222 A2</td>
<td>20-11-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2013223705 Al</td>
<td>29-08-2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wo 2012096878 A2</td>
<td>19-07-2012</td>
</tr>
<tr>
<td>US 2013072806  Al</td>
<td>21-03-2013</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td>US 2010030086  Al</td>
<td>04-02-2010</td>
<td>EP 2197345 Al</td>
<td>23-06-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2211702 Al</td>
<td>04-08-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010030086 Al</td>
<td>04-02-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010030087 Al</td>
<td>04-02-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wo 2010014442 Al</td>
<td>04-02-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wo 2010014931 Al</td>
<td>04-02-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2007255148 Al</td>
<td>01-11-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wo 2007127675 Al</td>
<td>08-11-2007</td>
</tr>
<tr>
<td>US 2005027322  Al</td>
<td>03-02-2005</td>
<td>US 2005027322 Al</td>
<td>03-02-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wo 2005011802 A2</td>
<td>10-02-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5021463 B2</td>
<td>05-09-2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2008501439 A</td>
<td>24-01-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2005288721 Al</td>
<td>29-12-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010286592 Al</td>
<td>11-11-2010</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
<td>Publication date</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>----------------</td>
<td>-------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>WO 2005120635 AI</td>
<td>22-12-2005</td>
<td></td>
<td></td>
</tr>
<tr>
<td>US 5139020 A 18-08-1992</td>
<td>NONE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WO 2006008535 AI 26-01-2006</td>
<td>AT 530222 T 15-11-2011</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AU 2005263981 AI 26-01-2006</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CA 2574528 AI 26-01-2006</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CN 101027098 A 29-08-2007</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EP 1778343 AI 02-05-2007</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HK 1101560 AI 14-09-2012</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>JP 5597344 B2 01-10-2014</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>JP 2008506491 A 06-03-2008</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>US 2009069859 AI 12-03-2009</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>WO 2006008535 AI 26-01-2006</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>